ArriVent BioPharma (AVBP) Update / Briefing June 23, 2025 08:00 AM ET Speaker0 Good morning and welcome to the Forte Biosciences Investor Webcast. At this time, all attendees are in a listen only mode. A Q and A session will follow the formal presentations. As a reminder, this call is being recorded and a replay will be made available on the Forte Biosciences Biosciences website following the conclusion of the event. I'd now like to turn the call over to Doctor. Paul Wagner, Chief Executive Officer of Forte ...

Group 1 - Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of therapeutic biologics aimed at selectively engaging and modulating disease-specific T cells for cancer and autoimmune disease treatment [1][3] - The company will host a conference call and webcast on April 15, 2025, at 4:30 p.m. ET to provide a business update [1][2] - Cue Biopharma's proprietary platform, Immuno-STAT™, is designed to harness the body's immune system by selectively modulating disease-specific T cells without broad systemic immune modulation [3] Group 2 - The company is headquartered in Boston, Massachusetts, and is led by a management team with expertise in immunology, protein engineering, and clinical development of protein biologics [4] - Investors can access the conference call via specific phone numbers and a webcast link, with the archived version available for 30 days [2]